Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)

被引：0
|
作者：
Ramalingam, S. S.
Maitland, M.
Frankel, P.
Argiris, A. E.
Koczywas, M.
Gitlitz, B.
Espinoza-Delgado, I.
Vokes, E. E.
Gandara, D. R.
Belani, C. P.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ So Calif, Los Angeles, CA USA
[6] NCI, Bethesda, MD 20892 USA
[7] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
[8] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8004
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer
    Lee, Siow Ming
    Rudd, Robin
    Woll, Penella J.
    Ottensmeier, Christian
    Gilligan, David
    Price, Allan
    Spiro, Stephen
    Gower, Nicole
    Jitlal, Mark
    Hackshaw, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5248 - 5254
  • [32] Phase I/II study of atrasentan, an endothelin a receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
    Chiappori, Alberto A.
    Haura, Eric
    Rodriguez, FranciscoA.
    Boulware, David
    Kapoor, Rachna
    Neuger, Anthony M.
    Lush, Richard
    Padilla, Barbara
    Burton, Michelle
    Williams, Charles
    Simon, George
    Antonia, Scott
    Sullivan, Daniel M.
    Bepler, Gerold
    CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1464 - 1469
  • [33] Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
    Shaw, Alice T.
    Ghizdavescu, Doru
    Jain, Minish
    Volovat, Constantin
    Subramaniam, Deepa
    Shuster, Dale
    Jin, Xiaoping
    Dutta, Dipen
    Pai, Seema
    von Roemeling, Reinhard
    CANCER RESEARCH, 2012, 72
  • [34] Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
    Mok, Tony S. K.
    Wu, Yi-Long
    Yu, Chong-Jen
    Zhou, Caicun
    Chen, Yuh-Min
    Zhang, Li
    Ignacio, Jorge
    Liao, Meilin
    Srimuninnimit, Vichien
    Boyer, Michael J.
    Chua-Tan, Marina
    Sriuranpong, Virote
    Sudoyo, Aru W.
    Jin, Kate
    Johnston, Michael
    Chui, Winsome
    Lee, Jin-Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5080 - 5087
  • [35] Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer
    Paz-Ares, Luis G.
    Biesma, Bonne
    Heigener, David
    von Pawel, Joachim
    Eisen, Timothy
    Bennouna, Jaafar
    Zhang, Li
    Liao, Meilin
    Sun, Yan
    Gans, Steven
    Syrigos, Kostas
    Le Marie, Etienne
    Gottfried, Maya
    Vansteenkiste, Johan
    Alberola, Vincente
    Strauss, Uwe Phillip
    Montegriffo, Elaine
    Ong, Teng Jin
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (25) : 3084 - 3092
  • [36] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
    Volovat, Constantin
    Bondarenko, Igor M.
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    SPRINGERPLUS, 2015, 4
  • [37] Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Heymach, J.
    Paz-Ares, L.
    De Braud, F.
    Sebastian, M.
    Stewart, D. J.
    Eberhardt, W.
    Herbst, S.
    Krebs, A.
    Langmuir, P.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer
    Li, Kun-lin
    Li, Li
    Zhang, Peng
    Kang, Jun
    Wang, Yu-bo
    Chen, Heng-yi
    He, Yong
    CLINICAL LUNG CANCER, 2017, 18 (03) : 340 - 343
  • [39] TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)
    Quoix, Elisabeth A.
    Nemunaitis, John J.
    Burzykowski, Tomasz
    Bastien, Berangere
    Lacoste, Gisele
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Crawford, Jeffrey
    Swanson, Paul
    Schwarzenberger, Paul
    Sandler, Alan
    Prager, Diane
    Zhang, Kathy
    Freeman, Daniel J.
    Johnson, Carol W.
    Krishnan, Kartik
    Johnson, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1510 - 1518
12345